Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready
Pretzel Therapeutics Inc. has 2 pending office actions in Biotechnology & Pharmaceuticals. The matters are assigned to 2 distinct examiners and 2 distinct art units, indicating separate examination settings for the current portfolio.
SHAMEEM, GOLAM M is the busiest examiner, with 1 pending matter. The current workload is therefore divided across the identified assignments rather than concentrated with that examiner. Counsel should evaluate each biotechnology and pharmaceutical matter on its own record, while comparing response timing and claim strategy internally without assuming that one examiner’s approach will govern the other matter.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §102 only | 1 (50%) |
| Multi-statute (no §101) | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| SHAMEEM, GOLAM M | 1 | 86.7% | +15.9% |
| ROBINSON, MIKHAIL O'DONNEL | 1 | 58.3% | +43.1% |
Cases in front of an examiner with an allow rate of 80%+ where the difficulty is Easy or Medium. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18687692 | ISOQUINOLINONES AND QUINOLINONES AS MODULATORS OF POLRMT | SHAMEEM, GOLAM M | — |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18687736 | HYDROXY AND ALKOXY COUMARINS AS MODULATORS OF POLRMT | ROBINSON, MIKHAIL O'DONNEL | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18687692 | ISOQUINOLINONES AND QUINOLINONES AS MODULATORS OF POLRMT | SHAMEEM, GOLAM M | — |
| 18687736 | HYDROXY AND ALKOXY COUMARINS AS MODULATORS OF POLRMT | ROBINSON, MIKHAIL O'DONNEL | — |
| Art Unit | Apps |
|---|---|
| 1621 | 1 |
| 1627 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18687692 | ISOQUINOLINONES AND QUINOLINONES AS MODULATORS OF POLRMT | SHAMEEM, GOLAM M | 1621 | §102 | Non-Final OA | — | Pending | Feb 28, 2024 |
| 18687736 | HYDROXY AND ALKOXY COUMARINS AS MODULATORS OF POLRMT | ROBINSON, MIKHAIL O'DONNEL | 1627 | §102§112 | Non-Final OA | — | Pending | Feb 28, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialPretzel Therapeutics Inc. has 2 pending office actions as of October 2026, spread across 2 art units and 2 examiners.
Golam M Shameem has the most, with 1 of Pretzel Therapeutics Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
